FibroGen Inc(FGEN) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Current Price

$20.64

RSI

38.718

Beta:

1.186431

March 01, 2021
38.6M
-9.6M

629.819 %
24.077 %
40.374 %
-64.474 %

$176,319,000
$256,577,000
$212,958,000
$125,668,000
$179,577,000
$180,828,000
-45.519 %
20.482 %
69.461 %
-42.898 %
-0.697 %

$-188,931,000
$-76,642,000
$-86,116,000
$-125,882,000
$-61,751,000
$-85,537,000
-59.434 %
12.361 %
46.177 %
-50.945 %
38.519 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.